MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients.
Antiemetic guidelines
Chemotherapy
Nausea
Patient advocates
Patients
Vomiting
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
10
04
2024
accepted:
03
05
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
10
5
2024
Statut:
epublish
Résumé
The Multinational Association of Supportive Care in Cancer (MASCC)/European Society of Medical Oncology (ESMO) Patient Antiemetic Guideline Committee aimed to (1) adapt the updated evidence-based, clinical guidelines to patient-centered antiemetic guidelines and (2) develop patient education materials and statements. The MASCC 2023 Patient Antiemetic Guidelines were created and reviewed by antiemetic experts and patient advocates by incorporating the 2023 MASCC/ESMO antiemetic guidelines into patient-friendly language. Patient Education Statements were developed based on current literature and by utilizing an expert modified Delphi consensus (≥ 75% agreement). Patient advocate/focus group input and patient survey results were further integrated into Patient-Centered Antiemetic Guidelines and Education Statements. Patient-Centered Antiemetic Guidelines were created using patient-friendly language and visual slides. Patient-friendly language was also utilized to communicate the Educational Statements. Key content categories identified for the Educational Statements included the following: nausea/vomiting definitions, causes, risk factors, categories, complications, accompanying symptoms, prophylactic antiemetic treatment, general management, when to call/what to ask the healthcare team, what caregivers can do, and available resources. All identified content met the ≥ 75% expert agreement threshold. Fifteen (15) items demonstrated 100% agreement, 11 items achieved ≥ 90% agreement, and three content items demonstrated 80 ~ 82% agreement. The inaugural MASCC 2023 Patient Antiemetic Guidelines can help patients and caregivers understand the prevention of nausea and vomiting related to their cancer treatment. Educational Statements provide further patient information. Educating patients on how to utilize guideline antiemetics and the education statements can contribute improvements in the control of anticancer treatment-related nausea and vomiting.
Identifiants
pubmed: 38727834
doi: 10.1007/s00520-024-08543-x
pii: 10.1007/s00520-024-08543-x
doi:
Substances chimiques
Antiemetics
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
335Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356–1367. https://doi.org/10.1056/NEJMra1515442
doi: 10.1056/NEJMra1515442
pubmed: 27050207
Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5–9. https://doi.org/10.1007/s00520-018-4131-3
doi: 10.1007/s00520-018-4131-3
pubmed: 29556808
pmcid: 5876280
Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28(6):1260–1267. https://doi.org/10.1093/annonc/mdx100
doi: 10.1093/annonc/mdx100
pubmed: 28398530
pmcid: 5452068
Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ (2019) ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27(1):87–95. https://doi.org/10.1007/s00520-018-4464-y
doi: 10.1007/s00520-018-4464-y
pubmed: 30284039
Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR (2018) Impact of patient involvement on clinical practice guideline development: a parallel group study. Implement Sci 13(1):55. https://doi.org/10.1186/s13012-018-0745-6
doi: 10.1186/s13012-018-0745-6
pubmed: 29661195
pmcid: 5902835
Addario B, Geissler J, Horn MK, Krebs LU, Maskens D, Oliver K, Plate A, Schwartz E, Willmarth N (2020) Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials. Health Expect 23(1):41–51. https://doi.org/10.1111/hex.12997
doi: 10.1111/hex.12997
pubmed: 31722131
Paterick TE, Patel N, Tajik AJ, Chandrasekaran K (2017) Improving health outcomes through patient education and partnerships with patients. Proc (Bayl Univ Med Cent) 30(1):112–113. https://doi.org/10.1080/08998280.2017.11929552
doi: 10.1080/08998280.2017.11929552
pubmed: 28152110
Molassiotis A, Zhao IY, Crichton M, Olver I, Fleury M, Giusti R, Scotte F, Affronti ML (2023) Effects of food-based interventions in the management of chemoradiotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 31(7):413. https://doi.org/10.1007/s00520-023-07879-0
doi: 10.1007/s00520-023-07879-0
pubmed: 37351633
Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage 34(2):148–159. https://doi.org/10.1016/j.jpainsymman.2006.10.018
doi: 10.1016/j.jpainsymman.2006.10.018
pubmed: 17509816
Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D (2012) Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw 10(2):149–157. https://doi.org/10.6004/jnccn.2012.0018
doi: 10.6004/jnccn.2012.0018
pubmed: 22308514